NASDAQ: MLTXMoonlake Immunotherapeutics Stock Ownership - Who owns Moonlake Immunotherapeutics?
Insider buying vs selling
Have Moonlake Immunotherapeutics insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Matthias Bodenstedt | Chief Financial Officer | 2025-10-08 | 10,870 | $9.09 | $98.81kBuy |
| Bihua Chen | Insider | 2025-09-30 | 5,827 | $6.96 | $40.56kSell |
| Bihua Chen | Insider | 2025-09-29 | 232,460 | $8.40 | $1.95MSell |
| Bihua Chen | Insider | 2025-09-29 | 2,800,000 | $6.61 | $18.51MSell |
| Bihua Chen | Insider | 2025-09-29 | 3,390,943 | $7.58 | $25.70MSell |
| Bihua Chen | Insider | 2025-09-29 | 70,748 | $9.38 | $663.62kSell |
| Catherine Moukheibir | Director | 2025-07-03 | 23,500 | $48.79 | $1.15MSell |
MLTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when MLTX insiders and whales buy or sell their stock.
MLTX Shareholders
What type of owners hold Moonlake Immunotherapeutics stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Bvf Inc | 30.75% | 19,751,284 | $189.81M | Institution |
| Cormorant Asset Management LP | 13.22% | 8,494,151 | $81.63M | Institution |
| Fmr LLC | 8.92% | 5,730,549 | $55.07M | Institution |
| Bihua Chen | 7.54% | 4,844,173 | $46.55M | Insider |
| Avoro Capital Advisors LLC | 6.46% | 4,150,000 | $39.88M | Institution |
| Helix Holdings LLC | 5.01% | 3,215,000 | $30.90M | Insider |
| Da Silva Jorge Santos | 4.79% | 3,078,577 | $29.59M | Insider |
| Kristian Reich | 4.69% | 3,009,940 | $28.93M | Insider |
| Price T Rowe Associates Inc | 4.07% | 2,613,233 | $25.11M | Institution |
| Citadel Advisors LLC | 2.61% | 1,674,041 | $16.09M | Institution |
MLTX vs Biotech Stocks
Moonlake Immunotherapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.